Correction: Dueñas et al. Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals.


Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 Jun 2021
Historique:
received: 22 03 2021
accepted: 31 05 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

In the original article, there was a mistake in Figure 3 as published [...].

Identifiants

pubmed: 34206709
pii: cancers13133104
doi: 10.3390/cancers13133104
pmc: PMC8268357
pii:
doi:

Types de publication

Published Erratum

Langues

eng

Subventions

Organisme : instituto de salud carlos III
ID : CM19/00099
Organisme : Catalan-Balearic Society of Oncology
ID : 2018 grant of the Catalan-Balearic Society of Oncology
Organisme : Spanish Ministry of Economy and Competitiveness
ID : SAF2015-68016-R
Organisme : CIBERONC
ID : 2017SGR1282
Organisme : Government of Catalonia
ID : PERIS SLT002/16/0037

Commentaires et corrections

Type : ErratumFor

Références

Cancers (Basel). 2020 Nov 18;12(11):
pubmed: 33218006

Auteurs

Nuria Dueñas (N)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.

Matilde Navarro (M)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.
Hereditary Cancer Program, Catalan Institute of Oncology, 08916 Badalona, Barcelona, Spain.

Àlex Teulé (À)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.

Ares Solanes (A)

Hereditary Cancer Program, Catalan Institute of Oncology, 08916 Badalona, Barcelona, Spain.

Mònica Salinas (M)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.

Sílvia Iglesias (S)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.

Elisabet Munté (E)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.

Jordi Ponce (J)

Department of Gynecology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.

Jordi Guardiola (J)

Department of Gastroenterology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.

Esther Kreisler (E)

Department of General Surgery, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.

Elvira Carballas (E)

Department of Gynecology, Trias i Pujol University Hospital, 08916 Badalona, Barcelona, Spain.

Marta Cuadrado (M)

Department of General Surgery, Trias i Pujol University Hospital, 08916 Badalona, Barcelona, Spain.

Xavier Matias-Guiu (X)

Department of Pathology, Bellvitge University Hospital, Hospitalet de Llobregat, 08908 Barcelona, Spain.

Napoleón de la Ossa (N)

Department of Pathology, Trias i Pujol University Hospital, 08916 Badalona, Barcelona, Spain.
Department of Pathology, Hospital General de Catalunya-Grupo Quironsalud, 08203 Barcelona, Spain.

Joan Lop (J)

Department of Pathology, Hospital del Mar Institute for Medical Research, 08003 Barcelona, Spain.

Conxi Lázaro (C)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.

Gabriel Capellá (G)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.

Marta Pineda (M)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.

Joan Brunet (J)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain.
Hereditary Cancer Program, Catalan Institute of Oncology-IDBIGI, 17007 Girona, Spain.

Classifications MeSH